FREE UNLIMITED IMAGE HOSTING

FREE UNLIMITED IMAGE HOSTING FOR ALL.

DizinPix.com is one of the best image-hosting resources to HIDE YOUR IMAGES AND LOCK IMAGES WITH PASSWORD.

UNDERSTOOD. YUM!
Get Full Information

Few people with peanut allergy tolerate peanut after stopping oral immunotherapy

Get Full Information
16 Views

Few people with peanut allergy tolerate peanut after stopping oral immunotherapy

Allergy to peanut, which is often severe, is one of the most common food allergies in the United States. Although previous studies have shown that peanut oral immunotherapy (OIT) — ingesting small, controlled amounts of peanut protein — can desensitize adults and children and prevent life-threatening allergic reactions, the optimal duration and dose is unknown. In a study that followed participants after OIT successfully desensitized them to peanut, discontinuing OIT or continuing OIT at a reduced dose led to a decline in its protective effects. The study, published online today in The Lancet, also found that several blood tests administered before OIT could predict the success of therapy. The Phase 2 study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and may inform who may benefit from peanut OIT and what changes in this experimental treatment should be implemented.

Investigators at Stanford University enrolled 120 people aged 7 to 55 with diagnosed peanut allergy in the Peanut Oral Immunotherapy Study: Safety Efficacy and Discovery, or POISED. While otherwise avoiding peanut throughout the trial, 95 participants received gradually increasing daily doses of peanut protein up to 4 grams, and 25 participants received daily placebo oat flour OIT. After 24 months, participants were given gradually increasing amounts of peanut in a controlled environment, to assess their tolerance. Of those participants who received peanut OIT, 83% passed the peanut challenge without an allergic reaction, while only 4% on placebo OIT did so.

Those on OIT who passed the challenge were then randomized to receive either placebo OIT or were switched to a 300-mg daily dose of peanut protein. One year later, more participants on 300-mg peanut OIT (37%) passed the challenge than those on placebo OIT (13%), confirming insights from smaller trials that desensitization is maintained in only a minority of participants after OIT is discontinued or reduced. Participants who passed food challenges also had lower initial levels of allergic antibodies to peanut protein and other indicators of allergic activity in the blood. Future research will focus on identifying optimal OIT regimens that maintain protection after therapy and will allow for regular food consumption without allergic symptoms.

Story Source:

Materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Content may be edited for style and length.

Get Full Information


Journal Reference:

  1. R Chinthrajah et al. Sustained outcomes in a large double-blind, placebo-controlled, randomized phase 2 study of peanut immunotherapy. The Lancet, 2019 DOI: 10.1016/S0140-6736

Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. “Few people with peanut allergy tolerate peanut after stopping oral immunotherapy: Continuing with a modest dose confers more protection.” ScienceDaily. ScienceDaily, 13 September 2019. .
NIH/National Institute of Allergy and Infectious Diseases. (2019, September 13). Few people with peanut allergy tolerate peanut after stopping oral immunotherapy: Continuing with a modest dose confers more protection. ScienceDaily. Retrieved September 13, 2019 from www.sciencedaily.com/releases/2019/09/190913120828.htm
NIH/National Institute of Allergy and Infectious Diseases. “Few people with peanut allergy tolerate peanut after stopping oral immunotherapy: Continuing with a modest dose confers more protection.” ScienceDaily. www.sciencedaily.com/releases/2019/09/190913120828.htm (accessed September 13, 2019).

Get Full Information

Get Full Information
allshango

Show comments

Recent Posts

Cancer cells prefer a 'comfort cruise,' follow predictable paths of least resistance

Cancer cells prefer a 'comfort cruise,' follow predictable paths of least resistance New research from a group of Vanderbilt biomedical…

23 mins ago

Researchers use light to control high-speed chemical reactions in a new way

Researchers use light to control high-speed chemical reactions in a new way Many natural and synthetic chemical systems react and…

23 mins ago

Verdict for China's efforts on coal emissions

Verdict for China's efforts on coal emissions Researchers from China, France and the USA have evaluated China's success in stemming…

23 mins ago

The rare molecule weighing in on the birth of planets

The rare molecule weighing in on the birth of planets Astronomers using one of the most advanced radio telescopes have…

23 mins ago

Engineers develop 'blackest black' material to date

Engineers develop 'blackest black' material to date With apologies to "Spinal Tap," it appears that black can, indeed, get more…

23 mins ago

India Vs South Africa 1st T20I in Dharamsala, Live Score: Rain delays toss, as both teams eye winning start

oi-Avinash Sharma New Delhi, Sep 13: Team India take on South Africa in the first Twenty20 International at Himachal Pradesh…

2 hours ago